Psychedelics, including psilocybin and MDMA, have gained increasing attention for their potential therapeutic benefits. Scientific research suggests that these substances may play a crucial role in treating mental health conditions like depression, PTSD, and substance use disorders. White papers provide a deeper look into the clinical, neurological, and policy-oriented aspects of psychedelics, offering valuable insights for researchers, medical professionals, and policymakers.

Understanding Psychedelic Research

Psychedelic research is at the forefront of a mental health revolution—one that has the potential to change countless lives. By understanding and supporting this research, we can help shape the future of psychedelic medicine.

Why White Papers Matter

White papers provide comprehensive, peer-reviewed research that helps shape public perception, inform healthcare professionals, and influence policymakers. As psychedelics move closer to regulatory approval, these papers serve as critical tools for advancing knowledge and advocating for safe, evidence-based psychedelic therapy.

Research

Disclaimer: The following links are provided for educational purposes only and do not imply endorsement of any substance, activity, or treatment. Please consult medical and legal professionals before making decisions related to psychedelics.

  • Summary: This paper explores the ethical and legal issues in psychedelic harm reduction and integration therapy, providing guidance on mitigating risks and practicing within legal and ethical boundaries.

    Learn more: https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-021-00489-1

  • Summary: This paper outlines the Food and Drug Administration’s (FDA) approach to psychedelic-assisted therapy, including regulatory frameworks, safety considerations, and the path toward potential approvals for MDMA, psilocybin, and other compounds.

    Learn more: https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs

  • Summary: This article from the National Institutes of Health (NIH) discusses how psychedelic drugs like psilocybin cause acute changes in perception and may have therapeutic effects by altering brain function.

    Learn more: https://www.nih.gov/news-events/nih-research-matters/how-psychedelic-drugs-alter-brain

  • Summary: This peer-reviewed article explores how psilocybin may help treat PTSD by interacting with serotonin receptors involved in fear, memory, and emotional processing. The authors highlight psilocybin’s potential to disrupt trauma loops and support therapeutic breakthroughs, calling for continued clinical research into its safety and effectiveness.

    Learn more: https://journals.sagepub.com/doi/10.1177/02698811241286771

  • Summary: Research from NYU Langone Health demonstrates the effectiveness of psilocybin in reducing alcohol dependence. This study found that two doses of psilocybin, combined with psychotherapy, reduced heavy drinking by 83% among participants with alcohol dependence.

    Learn more: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2795625

  • Summary: A landmark study published in JAMA Psychiatry demonstrates the effectiveness of psilocybin-assisted therapy in treating major depressive disorder. This research supports psilocybin’s potential as an alternative to traditional antidepressants.

    Learn more: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2772630

Get Involved

Support Research: Donate to organizations conducting groundbreaking psychedelic studies.

Advocate for Access: Encourage evidence-based policies that promote safe and legal psychedelic therapy.

Stay Informed: Keep up with the latest psychedelic research through trusted sources like MAPS, Johns Hopkins, and NYU.